（邯郸市第一医院肿瘤科，邯郸 056002）

摘　要：为研究银杏内酯B对食管癌细胞增殖和凋亡的作用及相关机制，采用体外培养人食管癌OE19细胞，将其分为对照组（不做干预）、低/中/高剂量试验组（分别加入6.25、12.50、25.00 μmol/L银杏内酯B）、银杏内酯B组（12.50 μmol/L银杏内酯B）、阳性药物组（4 mg/L顺铂）、抑制剂组［12.50 μmol/L银杏内酯B+10.00 μmol/L Janus激酶2/转录激活因子3（JAK2/STAT3）通路抑制剂AG490］、激活剂组（12.50 μmol/L银杏内酯B+0.50 μmol/L JAK2/STAT3通路激活剂Colivelin），干预24 h后，采用细胞计数试剂盒-8（CCK-8）、5-乙炔基-2'脱氧尿嘧啶核苷（EdU）法、Hoechst 33258染色法、实时荧光定量PCR（RT-qPCR）和蛋白免疫印迹（WB）法检测细胞的活力、增殖率、凋亡率及相关因子的表达水平。结果显示，与对照组相比，中/高剂量试验组与阳性药物组的细胞活力降低（P<0.05），因此，本研究选择有显著差异且较低浓度的12.50 μmol/L银杏内酯B作为银杏内酯B组进行后续试验。与对照组相比，银杏内酯B组和阳性药物组细胞的增殖率、Cyclin D1的mRNA和蛋白质、p-JAK2、p-STAT3蛋白的表达水平降低，凋亡率、Caspase-3的mRNA和蛋白质的表达水平升高（P<0.05）。与银杏内酯B组相比，抑制剂组各指标变化进一步增强（P<0.05），激活剂组则显著逆转了上述指标的变化（P<0.05）。银杏内酯B能够通过下调JAK2/STAT3信号通路抑制OE19细胞的增殖，促进食管癌细胞凋亡。本研究揭示了银杏内酯B新抗癌机制，为食管癌的研究提供了理论依据。

关键词：食管癌；银杏内酯B；Janus激酶2/转录激活因子3；增殖；凋亡

中图分类号：R318.14                           文献标志码：A            DOI：10.3969/j.issn.1007-7146.2024.02.011

(Department of Oncology, Handan First Hospital, Handan 056002, China)

Abstract: To investigate the effects of ginkgolide B on the proliferation and apoptosis of esophageal cancer cells and the related mechanisms. Human esophageal cancer OE19 cells were cultured in vitro. They were divided into control group (no intervention), low/medium/high dose test group (adding 6.25, 12.50 and 25.00 μmol/L ginkgolide B, respectively), ginkgolide B group (12.50 μmol/L ginkgolide B), positive drug group (4 mg/L cisplatin) and inhibitor group ［12.50 μmol/L ginkgolide B+10.00 μmol/L janus kinase 2/transcriptional activator 3 (JAK2/STAT3) pathway inhibitor AG490］ and activator group (12.50 μmol/L ginkgolide B+0.50 μmol/L JAK2/STAT3 pathway activator Colivelin), 24 h after intervention, cell count kit 8 (CCK-8), 5-acetyl-2' deoxyuridine (EdU) method, Hoechst 33258 staining, real-time fluorescence quantitative PCR (RT-qPCR) and protein immunoblot (WB) were used to detect cell viability, proliferation rate, apoptosis rate and expression levels of related factors. The results show that: compared with the control group, the cell viability of the medium/high dose test group and positive drug group was decreased (P<0.05), therefore, in this study, 12.50 μmol/L ginkgolide B group with significant difference and lower concentration was selected as ginkgolide B group for follow-up tests. Compared with the control group, the cell proliferation rate, Cyclin D1 mRNA and protein expression levels, p-JAK2 and p-STAT3 protein expression levels of ginkgolide B group and positive drug group were decreased, while the apoptosis rate and Caspase-3 mRNA and protein expression levels were increased (P<0.05). Compared with the ginkgolide B group, the changes of all indexes in inhibitor group were further enhanced (P<0.05). while those in activator group were significantly reversed (P<0.05). Ginkgolide B can inhibit the proliferation of OE19 cells and promote apoptosis of esophageal cancer cells by down-regulating JAK2/STAT3 signaling pathway. This study revealed a new anticancer mechanism of ginkgolide B and provided a theoretical basis for the study of esophageal cancer.

Key words: esophageal cancer; ginkgolide B; janus kinase 2/transcriptional activator 3; proliferation; apoptosis

（Acta Laser Biology Sinica, 2024, 33(2): 185-192）